Altrafin AG Invests $8.91 Million in Novo Nordisk A/S $NVO

Key Points

• Altrafin AG opened a new position in Novo Nordisk during the fourth quarter, buying 175,183 shares worth about $8.91 million. The stake represents roughly 2.8% of Altrafin’s portfolio and is its 14th largest holding.
• A major positive catalyst for Novo Nordisk was UK approval of its daily Wegovy pill, the first GLP-1 weight-loss tablet authorized in the country. The approval could broaden the company’s obesity franchise beyond injections and create a new growth channel.
• Despite the positive news, the stock faces some headwinds, including a reported cyber incident involving unauthorized internal system access and concerns that some U.S. employers may reduce GLP-1 coverage in 2027. Analysts remain cautious overall, with the stock carrying an average Hold rating.

Altrafin AG bought a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 175,183 shares of the company's stock, valued at approximately $8,913,000. Novo Nordisk A/S makes up approximately 2.8% of Altrafin AG's portfolio, making the stock its 14th largest position.

Other institutional investors also recently added to or reduced their stakes in the company. Godfrey Financial Associates Inc. acquired a new position in Novo Nordisk A/S during the fourth quarter worth approximately $25,000. WealthCollab LLC increased its position in Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company's stock worth $27,000 after buying an additional 260 shares during the period. American National Bank & Trust acquired a new position in Novo Nordisk A/S during the fourth quarter worth approximately $28,000. Maseco LLP acquired a new position in Novo Nordisk A/S during the fourth quarter worth approximately $29,000. Finally, Jackson Grant Investment Advisers Inc. acquired a new position in Novo Nordisk A/S during the fourth quarter worth approximately $29,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: UK regulators approved Novo Nordisk’s daily Wegovy pill, making it the first GLP-1 weight-loss tablet approved in the UK. That expands the company’s obesity franchise beyond injections and could open a new growth channel. UK approves Novo weight-loss pill to edge open European market
• Positive Sentiment: Several follow-up reports highlighted the UK approval as a milestone that could help Novo regain momentum in the obesity market and broaden access to Wegovy through private prescriptions. Novo Nordisk Wegovy pill becomes first daily GLP-1 weight-loss pill approved in the UK
• Positive Sentiment: Analysts also raised FY2026 EPS estimates slightly, signaling still-solid earnings expectations despite recent share-price weakness. Novo Nordisk A/S Trading Down 0.1%
• Neutral Sentiment: Some commentary on the “Wegovy pill” said the approval is encouraging but not yet enough to make certain investors buy, suggesting the market may want more proof of commercial impact before re-rating the stock. Novo Nordisk: Wegovy Pill Is Encouraging But Still Not Enough To Make Me Buy
• Negative Sentiment: Novo Nordisk disclosed an IT security incident involving unauthorized access to internal systems and potential data copying, which could pressure investor confidence even though the company said operations were not materially affected. Novo Nordisk hit by cyber incident, probes data breach
• Negative Sentiment: Another report said some U.S. employers may drop GLP-1 obesity-drug coverage in 2027, a potential headwind for long-term demand and reimbursement for Wegovy and rival products. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

Wall Street Analyst Weigh In

Several research analysts have commented on NVO shares. Weiss Ratings lowered Novo Nordisk A/S from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Wednesday, April 22nd. JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. Kepler Capital Markets lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Tuesday, February 24th. Morgan Stanley raised Novo Nordisk A/S from an "underweight" rating to an "equal weight" rating and set a $40.00 price target on the stock in a research report on Tuesday, March 3rd. Finally, The Goldman Sachs Group reaffirmed a "neutral" rating and set a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Four analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of "Hold" and an average price target of $65.56.

Novo Nordisk A/S Trading Down 0.1%

Shares of NVO stock opened at $43.90 on Friday. The business's 50 day moving average is $42.28 and its two-hundred day moving average is $46.00. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $81.44. The company has a market capitalization of $196.02 billion, a P/E ratio of 10.31, a price-to-earnings-growth ratio of 3.92 and a beta of 0.78. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The company had revenue of $10.85 billion for the quarter. Equities analysts forecast that Novo Nordisk A/S will post 3.45 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.